There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
We developed a model characterizing rates and costs of pneumococcal disease in the
US to estimate the expected annual clinical and economic burden of this condition
among older adults. Among the 91.5 million US adults aged >or=50 years, 29,500 cases
of invasive pneumococcal disease, 502,600 cases of nonbacteremic pneumococcal pneumonia,
and 25,400 pneumococcal-related deaths are estimated to occur yearly; annual direct
and indirect costs are estimated to total $3.7 billion and $1.8 billion, respectively.
Pneumococcal disease remains a substantial burden among older US adults, despite increased
coverage with PPV23 and indirect benefits afforded by PCV7 vaccination of young children.
Copyright 2010 Elsevier Ltd. All rights reserved.